Background Neurological and ophthalmological neurodegenerative diseases in large part
share underlying biology and pathophysiology. Despite extensive preclinical research on …

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …

Answer ALS is a biological and clinical resource of patient-derived, induced pluripotent stem
(iPS) cell lines, multi-omic data derived from iPS neurons and longitudinal clinical and …

A lack of stratification methods in patients with amyotrophic lateral sclerosis (ALS) is likely
implicated in therapeutic failures. Regional diversities and pathophysiological abnormalities …

Despite the improvements in life expectancy, neurodegenerative conditions have arguably
become the most dreaded maladies of older people. The neuroprotective and anti-ageing …

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that
primarily attacks motor neurons in the brain and spinal cord, leading to progressive paralysis …

Thoughtful clinical trial design is critical for efficient therapeutic development, particularly in
the field of amyotrophic lateral sclerosis (ALS), where trials often aim to detect modest …

Background Interventional trials in amyotrophic lateral sclerosis (ALS) suffer from the
heterogeneity of the disease as it considerably reduces statistical power. We asked if blood …

Background Based on the results of randomized, double-blind, placebo-controlled trials, the
benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain …

Amyotrophic lateral sclerosis (ALS), characterized by a loss of motor neurons in the brain
and spinal cord, is a relatively rare but currently incurable neurodegenerative disease. The …